Establishment of a value assessment framework for orphan medicinal products in China
MCDA is feasible for the value assessment of orphan drugs in China and can be used as a supplementary tool for drug access decisions in medical insurance. It is suggested to further improve the value assessment framework of orphan medicinal products, scientifically evaluate the MCDA framework weighting method, explore a framework system suitable for China's national conditions.
Authors
- Xian Tang (ORCID: https://orcid.org/0000-0003-0235-995X)
- Ming Hu (ORCID: https://orcid.org/0000-0002-3637-4130)
- Yuliang Xiang (ORCID: https://orcid.org/0000-0001-5856-6654)
- Handong Chen
Institutions
- Sichuan University (CN)
- Fudan University (CN)
- Shanghai Public Health Clinical Center (CN)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2024-10-20
- DOI
- https://doi.org/10.1186/s13023-024-03393-6
- Citations
- 5
- Primary Topic
- Research studies in Vietnam
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- National Natural Science Foundation of China